Drug Search Results
More Filters [+]

Octocog alfa

Alternative Names: octocog alfa, helixate, kogenate, helixate fs, kogenate fs
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Coagulation Factor

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Chile | Colombia | Croatia | Cyprus | Denmark | Egypt | France | Germany | Hong Kong | Hungary | Italy | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Portugal | Romania | Russia | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Octocog alfa

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events